华恒生物(688639) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥522,813,388.64, representing a year-over-year increase of 1.66%[2] - The net profit attributable to shareholders for Q3 2024 was ¥20,185,971.99, a decrease of 84.32% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥18,128,594.15, down 85.56% year-over-year[2] - The basic earnings per share for Q3 2024 was ¥0.09, a decline of 84.28% compared to the same period last year[3] - Total operating revenue for the first three quarters of 2024 reached ¥1,539,034,126.35, an increase of 12.85% compared to ¥1,364,161,262.06 in the same period of 2023[13] - Net profit for the first three quarters of 2024 was ¥167,996,718.70, a decrease of 47.56% from ¥319,399,135.43 in the same period of 2023[15] - The total comprehensive income for the third quarter of 2024 was CNY 167,800,467.05, compared to CNY 319,399,135.43 in the same period of 2023, indicating a significant decrease[17] - Basic and diluted earnings per share for the third quarter were CNY 0.74, down from CNY 1.40 in the previous year[17] Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥4,704,240,077.16, reflecting an increase of 18.49% from the end of the previous year[3] - The total current assets increased to CNY 1,239,970,610.67 from CNY 1,050,046,406.02, representing an increase of approximately 18.1% year-over-year[10] - Total liabilities increased to ¥2,848,853,312.27 in Q3 2024, compared to ¥2,144,577,318.12 in Q3 2023, marking a rise of 32.83%[12] - The company's total non-current assets reached ¥3,464,269,466.49, an increase of 18.63% from ¥2,920,191,687.28 in the previous year[12] - The company's short-term borrowings rose to ¥1,346,423,032.90, up 47.10% from ¥915,121,195.63 in the same period last year[12] - The equity attributable to shareholders of the parent company was ¥1,858,594,150.65, slightly up from ¥1,826,971,175.81 in the previous year[12] Cash Flow - The net cash flow from operating activities for the year-to-date period decreased by 71.73% to ¥104,606,628.36[3] - Cash inflow from operating activities totaled CNY 1,661,699,060.61, an increase from CNY 1,395,423,545.57 year-over-year[18] - Cash outflow from operating activities was CNY 1,557,092,432.25, compared to CNY 1,025,434,972.19 in the same period last year[18] - Net cash flow from operating activities was CNY 104,606,628.36, a decrease from CNY 369,988,573.38 in the previous year[18] - Net cash flow from investing activities was -CNY 631,406,092.91, compared to -CNY 774,817,204.53 in the same period of 2023[19] - Net cash flow from financing activities was CNY 609,956,719.40, up from CNY 432,985,012.36 year-over-year[19] - The cash and cash equivalents at the end of the period amounted to CNY 445,305,816.80, compared to CNY 181,118,810.44 at the end of the same period last year[19] Research and Development - Research and development expenses for Q3 2024 totaled ¥27,162,038.22, which is 5.20% of the revenue, an increase of 0.74 percentage points year-over-year[3] - Research and development expenses increased to ¥90,514,239.06 in 2024, compared to ¥77,313,400.23 in 2023, reflecting a growth of 16.56%[15] - The company aims to leverage new technologies in its research and development efforts to improve operational efficiency and product offerings[9] Strategic Initiatives - The company plans to expand its market presence and invest in new product development to drive future growth[9] - The company is exploring potential mergers and acquisitions to enhance its competitive position in the biotechnology sector[9] - The management expressed optimism about future revenue growth driven by increased demand for its products and services[9] - The company experienced a significant decline in net profit primarily due to a decrease in the price of valine products compared to last year[6] Shareholder Information - The company reported a total of 7,426 common shareholders at the end of the reporting period[7] - The company's financial expenses increased significantly to ¥19,426,386.99 in 2024, compared to a negative expense of -¥3,448,594.55 in 2023[15]